Acinetobacter baumanii (A. baumanii) has arisen as the most important cause of nosocomial infection, typically in severely ill patients with many comorbidities and medical supportive devices. Tigecycline is a therapeutic option for treating this infection because of its potential ability against wide spectrum of bacterias, including multi-drug resistance A. baumannii (MDRAB). Our study determine the in vitro susceptibility of tigecycline against A. baumanii isolates and the emergence of MDRAB. The frequency of isolates that were not inhibited at MIC ≤ 0.5 µg/ml was 50.46%, at MIC = 1µg/ml was 2.38%, and at MIC = 2 µg/ml was 19.07%. The susceptibility rate of tigecycline against A. baumanii was 68.27% in 2015, 79.58% in 2016, and 67.87% in 2017. In vitro result demonstrated that tigecycline had good value of MIC against A. baumanii at the range of 0.5 to 2 µg/ml.
Introduction
A. baumanii is a pleomorphic Gram negative bacilli, that accounts for approximately 17 .44% of reported nosocomial infections in Indonesia. 1 This organism typically affects immunocompromised patients with medical devices, with high incidences and difficult-totreat infection due to the resistance of the bacteria. In the past decades, the rise of severe infection by this bacteria was related to the lower proportion of susceptible A. baumanii isolates which induced high mortality. 2, 3 Over the past few decades, clinicians have noticed a significant increase in the rate of multidrug resistance A. baumannii (MDRAB). The emergence of this multi-drug resistant organism has impacted on the choice of antibiotic therapy which becoming limited, and subsequently to prolonged length-of-stay along with inflated general costs of hospitalization. The new molecule tigecycline is one of the few therapeutic options against MDRAB. [2] [3] [4] [5] Tigecycline, a newer derivate minocycline, is a glycylcyclines that strongly counter a broad range of both Gram negative and positive 4, 6 The addition of a 9-tbutyl-glycylamido side chain affects the bacterial ribosomes with high affinity and active drug efflux, therefore inhibits the primary resistance mechanisms of tetracycline. 4, [6] [7] Information regarding this organism and their antibiotic susceptibility profiles among hospitalized patients in Indonesia is scarce. In our hospital, the multi-drug resistant organisms was prevalent across both Gram positive and negative bacterial genera due to excessive antibiotic use. Thus, the objective of the present study was to appraise in vitro susceptibility of tigecycline against A. baumanii isolates and the emergence of MDRAB. The frequency of A. baumanii was higher in year 2016. As the number of isolates of A. baumanii decreased from January -June 2016 period to July -December 2017, the tigecycline sensitivity against it increased for the same period ( Figure  1) . From a total of 692 A. baumanii isolates, tigecycline MIC ranged from ≤ 0.5 to ≥ 8 µg/ml ( Table 2. ). Most of A. baumanii isolated in the study were multi-drug resistant with good susceptibility to tigecycline. Detailed result the activity of tigecycline were shown in Table 2 , as well as Figure 1 . This study identified 50.46% isolates had MIC ≤ 0.5 µg/ml, 2.38% with MIC = 1 µg/ml, and 19.07% with MIC = 2 µg/ml. The susceptibility rate for A. baumanii (MIC ≤ 2 μg/ml) were 68.27% in 2015, 79.58% in 2016, and 67.87% in 2017. During the past decades, the incidence of multidrug resistance A. baumanii particularly carbapenem-resistant has accounted for approximately 93% of reported infection in hospital setting. 11 Therefore, therapeutic options available for infected patients are limited, as the strain frequently exhibit high resistance to most existing antibiotics. 4, 7, [11] [12] Several studies from different geographical regions found that the prevalence of MDRAB infection/colonization varied from 17.2% to 92.89%.
Materials and Methods

This
1,10-14, Thus, tigecycline is considered as the last option in the management of clinical infection caused by MDRAB.
Tigecycline MIC for A. baumanii in this study varied from ≤ 0.5 to ≥ 8 µg/ml, that was comparable with a study by Talaga K, et al. which found that ESBL-producing A. baumanii, likewise isolates non-carbapenemases, had the highest MIC level of 8.0 µg/ml; for AmpCproducing A. baumanii the highest MIC level was 6.0 µg/ml; and for MBL-producing isolates the MIC level was 2.0 µg/ml. 2 Since there was no reference MIC value for in vitro tigecycline susceptibility against A. baumanii, a suitable congruence of various tigecycline MIC value sensitivity test by Pieewngam and Kiratisin was used, with sensitive at MIC ≤ 0,5 and resistant at MIC > 2 µg/ml. 2, 15 These values were different with EUCAST reference which MIC ≥ 1 µg/ml was regarded as resistant as these resistant strains do not have mutation that enables them to acquire resistance. 2 The present study noted that tigecycline had a good in vitro activity against all isolates tested. This result is in contrast with a study from European country, where tigecycline showed activity of 50% or lower against MDRAB isolates. [6] [7] 16 On the other side, previous studies conducted in other province in Indonesia and India revealed high susceptibility of tigecycline (75% and 82 -88% respectively), although a sharp decline in the recent years has been marked. 1 
Conclusion
As tigecycline demonstrated good value of MIC in this study, ranging between ≤ 0,5 to ≤ 2 µg/ml, it could be considered an effective antibiotic against A. baumanii, especially MDRAB. Due to the absence of bactericidal activity of tigecycline, these result must be interpreted cautiously before using tigecycline for infection due to MDR organisms, particularly MDRAB. The susceptibility rate of tigecycline against MDR isolates is alarming, thus wise consumption is warranted to prevent further increase of MDR organism.
